Nemaura Medical to Present at the H.C. Wainwright Global Hybrid Investment Conference
Nemaura Medical (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will present virtually at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nemaura Medical (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will present virtually at the H.C. Wainwright Global Hybrid Investment Conference from May 23 – 26, 2022. The presentation is scheduled for May 24, 2022, available on demand starting at 7:00am ET. Dr. Chowdhury will discuss recent business developments and engage in one-on-one investor meetings. Nemaura specializes in wearable diagnostic devices, focusing on sugarBEAT®, a non-invasive glucose monitor, and the proBEAT™ system, integrating AI for diabetes management.
Details
News Market Reaction – NMRD
The recorded move for NMRD in the trading session of this news was +0.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Loughborough, England, May 19, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present virtually at the H.C. Wainwright Global Hybrid Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL.
Presentation Date: May 24, 2022
Time: On demand as of 7:00am ET
Dr. Chowdhury will provide updates on recent business developments. In addition, Dr. Chowdhury will be available for one-on-one meetings with investors who are registered to attend the conference. To request a meeting and to register for the conference, click below:
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and commercializing wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT® diabetes program that is currently undergoing pilot studies.
Additionally, Nemaura has launched Miboko, a new metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.